Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Employees - 2, CEO - Jeffrey Frelick, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -11.95, Piotroski Score(max is 10): 3, Working Capital: $6596074, Total Assets: $7002216, Retained Earnings: $-86778989, EBIT: -5269582, Total Liabilities: $406142, Revenue: $0

AryaFin Target Price - $2.19 - Current Price $ - Analyst Target Price $